Potential positive outcomes include reduced headache frequency and severity, improved quality of life for women suffering from hormonal-related headaches, and enhanced understanding of gender-specific treatment efficacy.
The primary outcome is a reduction in migraine frequency and intensity after 12 weeks of treatment. Secondary outcomes include improvements in photosensitivity, retinal vessel changes, and blood biomarker concentrations related to vascular tone.
Significant reduction in headache frequency and headache-related disability was observed 6 and 12 months after the therapy program, with median headache days decreasing from 30 at baseline to 13 at 12 months.
Patients reported a mean improvement of 72% in headaches on the treated side. Significant reductions in headache days (from 18.3 to 11.1 days/month), severity (from 7.8 to 5.4), and need for emergency care (from 3.6 to 0.71 visits/year) were observed after treatment of TOS.
Propranolol significantly reduced stroke risk in female migraine patients, particularly those with migraines without aura. The odds ratios indicated a substantial reduction in stroke risk over time, with lower stroke rates observed at 1, 2, 5, and 10 years in treated patients.